Deakin University

File(s) under permanent embargo

Transgenic swine: expression of human CD39 protects against myocardial injury

Version 2 2024-06-03, 18:13
Version 1 2018-07-10, 10:43
journal contribution
posted on 2024-06-03, 18:13 authored by Debra G Wheeler, Matthew E Joseph, Shouvik D Mahamud, William L Aurand, Peter J Mohler, Vincent J Pompili, Karen M Dwyer, Mark B Nottle, Sharon J Harrison, Anthony JF d'Apice, Simon C Robson, Peter J Cowan, Richard J Gumina
UNLABELLED: CD39 (ectonucleoside triphosphate diphosphohydrolase-1; ENTPD-1) rapidly hydrolyzes ATP and ADP to AMP; AMP is hydrolyzed by ecto-5'-nucleotidase (CD73) to adenosine, an anti-thrombotic and cardiovascular protective mediator. While expression of human CD39 in a murine model of myocardial ischemia/reperfusion (I/R) injury confers cardiac protection, the translational therapeutic potential of these findings requires further testing in a large animal model. To determine if transgenic expression of CD39 reduces infarct size in a swine model of myocardial ischemia/reperfusion injury, transgenic pigs expressing human CD39 (hCD39) were generated via somatic cell nuclear transfer and characterized. Expression of hC39 in cardiac tissue was confirmed by immunoblot and immunohistochemistry. Myocardial I/R injury was induced by intracoronary balloon inflation in the left anterior descending (LAD) artery for 60 min followed by 3 hours of reperfusion. The ischemic area was delineated by perfusion with 5% phthalo blue and the myocardial infarct size was determined by triphenyl tetrazolium chloride (TTC) staining. During ischemia, the rate-pressure product was significantly lower in control versus hCD39-Tg swine. Following reperfusion, compared to littermate control swine, hCD39-Tg animals displayed a significant reduction in infarct size (hCD39-Tg: 17.2 ± 4.3% vs. CONTROL: 44.7 ± 5.2%, P=0.0025). Our findings demonstrate for the first time that the findings in transgenic mouse models translate to large animal transgenic models and validate the potential to translate CD39 into the clinical arena to attenuate human myocardial ischemia/reperfusion injury.



Journal of molecular and cellular cardiology






Amsterdam, The Netherlands





Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2012, Elsevier